Experimental Therapeutics

实验治疗计划(ETP)的总体目标是建立一个世界级的学术中心，致力于为设计创新和有效的癌症治疗方案架起基础科学和转化科学的桥梁。该计划最初命名为分子治疗计划，成立于2004年12月，汇集了来自15个不同部门的41名研究人员组成的跨学科小组。自上一个资助周期以来，实验治疗方案的研究基数增加了104%，从7,878,482美元增加到16,042,852美元，其中年度直接研究支持总额为3,683,482美元，其中3,683,482美元来自NCI。在上一次赠款期间，实验治疗方案成员共有539份出版物，其中9.3%是方案内出版物，21.1%是方案间出版物。在王少蒙博士和朱迪思·塞伯特-利奥波德博士的领导下，ETP非常注重小分子靶向疗法的合理设计和开发，是基础科学和临床计划之间的关键纽带。ETP有四个主要研究主题： I)发现针对人类癌症中失调的关键信号通路的新的治疗剂和方法， 二)利用纳米技术平台改进药物输送系统，以解决肿瘤难以获得的问题； 3)实施先导优化和临床前生物标记物研究，以指导开发候选人的选择和临床试验设计， 四)将这些新的抗癌药物和方法转化为临床。

The overarching goal of the Experimental Therapeutics Program (ETP) is to build a world-class academic center dedicated to bridging basic and translational science for the design of Innovative and Impactful cancer therapies. This program, originally named the Molecular Therapeutics program, was established in December 2004 and brings together an interdisciplinary group of 41 investigators from 15 different departments. Since the last funding cycle the research base of the Experimental Therapeutics Program increased 104% from $7,878,482 to $16,042,852 total annual direct support with a total annual direct research support, of which $3,683,482 is from the NCI. Over the last grant period, there were a total of 539 publications of the Experimental Therapeutics Program members, of which 9.3% are intra-programmatic and 21.1% are inter-programmatic. Led by Shaomeng Wang, Ph.D. and Judith Sebolt-Leopold, Ph,D., the ETP has a strong focus on the rational design and development of small-molecule targeted therapies and serves as a critical link between the basic science and clinical programs. The ETP has four major research themes: I) Identification of novel therapeutic agents and approaches that target key signaling pathways dysregulated in human cancer, II) Improvement of drug delivery systems to address tumor inaccessibility using nanotechnology platforms, III) Execution of lead optimization and preclinical biomarker studies to guide development candidate selection and clinical trial design, IV) Translation of these new cancer medicines and approaches into the clinic.